CARA Therapeutics

ISIN US1407551092






CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States


Key metrics

Market capitalisation, EUR 37.32 m
EPS, EUR -2.02
P/B ratio 0.67
P/E ratio -
Dividend yield 0.00%

Income statement (2023)

Revenue, EUR 19.40 m
Net income, EUR -109.62 m
Profit margin -565.21%

What ETF is CARA Therapeutics in?

There are 2 ETFs which contain CARA Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of CARA Therapeutics is the CSIF (IE) MSCI USA Small Cap ESG Leaders Blue UCITS ETF B USD.
ETF Weight Investment focus Holdings TER Fund size (in m EUR) Return 1Y WKN ISIN
CSIF (IE) MSCI USA Small Cap ESG Leaders Blue UCITS ETF B USD 0.02%
United States
Small Cap
723 0.20% 436 +14.83% A2P4U1 IE00BMDX0L03
SPDR Russell 2000 US Small Cap UCITS ETF 0.00%
United States
Small Cap
1,795 0.30% 2,513 +15.85% A1XFN1 IE00BJ38QD84
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.